Bioventus (BVS) Enters Settlement Agreement

Go back to Bioventus (BVS) Enters Settlement Agreement

Bioventus Enters into Settlement Agreement to Preserve Maximum Optionality – Up To $350mm of Potential Liability Reduction and a Release of Future Claims related to the CartiHeal Acquisition

February 28, 2023 7:30 AM UTC

DURHAM, N.C., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (Bioventus or the Company), a global leader in innovations for active healing, announced today that it has entered into a Settlement Agreement (the Settlement Agreement) with the former CartiHeal shareholders (the CartiHeal Sellers) regarding the Companys obligations under the amended Option and Equity Purchase Agreement for its prior acquisition of CartiHeal (the Amended Acquisition Agreement).

The Settlement... More